Benzinga | Nov 3, 2020 04:01PM EST

Acorda Therapeutics Q3 EPS $(0.23) Beats $(0.31) Estimate, Sales $53.09M Beat $29.29M Estimate

Acorda Therapeutics (NASDAQ:ACOR) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.31) by 25.81 percent. This is a 50 percent increase over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $53.09 million which beat the analyst consensus estimate of $29.29 million by 81.26 percent. This is a 11.25 percent increase over sales of $47.72 million the same period last year.